INTERVENTION 1:	Intervention	0
Dose Level 1	Intervention	1
Gemcitabine at 1000 mg/m2 administered intravenously over 30 to 60 minutes on Days 1 and 8 in each 3-week (21-day) cycle of study therapy.	Intervention	2
gemcitabine	CHEBI:175901	0-11
INTERVENTION 2:	Intervention	3
Dose Level 2	Intervention	4
Gemcitabine at 1250 mg/m2 administered intravenously over 30 to 60 minutes on Days 1 and 8 in each 3-week (21-day) cycle of study therapy.	Intervention	5
gemcitabine	CHEBI:175901	0-11
Inclusion Criteria:	Eligibility	0
Histologically and/or cytologically confirmed breast cancer	Eligibility	1
breast cancer	DOID:1612	46-59
Received prior chemotherapy for metastatic breast cancer with anthracycline and taxane regimen	Eligibility	2
breast cancer	DOID:1612	43-56
anthracycline	CHEBI:48120	62-75
taxane	CHEBI:36064	80-86
To have at least one measurable region	Eligibility	3
PS: 0-1	Eligibility	4
To have adequate organ function (bone marrow, liver and renal function)	Eligibility	5
organ	UBERON:0000062	17-22
function	BAO:0003117,BFO:0000034	23-31
function	BAO:0003117,BFO:0000034	62-70
bone marrow	UBERON:0002371	33-44
liver	UBERON:0002107	46-51
Exclusion Criteria:	Eligibility	6
To have Interstitial pneumonia or pulmonary fibrosis	Eligibility	7
pneumonia	HP:0002090,DOID:552	21-30
pulmonary fibrosis	HP:0002206,DOID:3770	34-52
To have inflammatory carcinoma	Eligibility	8
carcinoma	HP:0030731,DOID:305	21-30
Within 28 days after the latest chemotherapy or radiotherapy, 14 days after the latest hormonal/immunotherapy or 7 days after surgery	Eligibility	9
radiotherapy	OAE:0000235	48-60
surgery	OAE:0000067	126-133
To have brain metastasis with symptom	Eligibility	10
brain	UBERON:0000955	8-13
symptom	OGMS:0000020	30-37
To have severe complication (cardiac infarction, infection, drug hyper sensitivity or diabetes)	Eligibility	11
severe	HP:0012828	8-14
drug	CHEBI:23888	60-64
Outcome Measurement:	Results	0
Tumor Response	Results	1
Best response recorded from the start of treatment until disease progression/recurrence using Response Evaluation Criteria In Solid Tumors (RECIST) criteria that defines when participants improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatment.	Results	2
disease	DOID:4,OGMS:0000031	57-64
stable	HP:0031915	225-231
Time frame: baseline to measured progressive disease	Results	3
time	PATO:0000165	0-4
progressive	HP:0003676	33-44
disease	DOID:4,OGMS:0000031	45-52
Results 1:	Results	4
Arm/Group Title: Dose Level 1	Results	5
Arm/Group Description: Gemcitabine at 1000 mg/m2 administered intravenously over 30 to 60 minutes on Days 1 and 8 in each 3-week (21-day) cycle of study therapy.	Results	6
gemcitabine	CHEBI:175901	23-34
Overall Number of Participants Analyzed: 6	Results	7
Measure Type: Number	Results	8
Unit of Measure: participants  Complete Response: 0	Results	9
Partial Response: 0	Results	10
Long Stable Disease: 1	Results	11
stable	HP:0031915	5-11
disease	DOID:4,OGMS:0000031	12-19
Stable Disease: 1	Results	12
stable	HP:0031915	0-6
disease	DOID:4,OGMS:0000031	7-14
Progressive Disease: 2	Results	13
progressive	HP:0003676	0-11
disease	DOID:4,OGMS:0000031	12-19
Not Evaluable: 2	Results	14
Results 2:	Results	15
Arm/Group Title: Dose Level 2	Results	16
Arm/Group Description: Gemcitabine at 1250 mg/m2 administered intravenously over 30 to 60 minutes on Days 1 and 8 in each 3-week (21-day) cycle of study therapy.	Results	17
gemcitabine	CHEBI:175901	23-34
Overall Number of Participants Analyzed: 62	Results	18
Measure Type: Number	Results	19
Unit of Measure: participants  Complete Response: 1	Results	20
Partial Response: 4	Results	21
Long Stable Disease: 4	Results	22
stable	HP:0031915	5-11
disease	DOID:4,OGMS:0000031	12-19
Stable Disease: 16	Results	23
stable	HP:0031915	0-6
disease	DOID:4,OGMS:0000031	7-14
Progressive Disease: 32	Results	24
progressive	HP:0003676	0-11
disease	DOID:4,OGMS:0000031	12-19
Not Evaluable: 5	Results	25
Adverse Events 1:	Adverse Events	0
Total: 1	Adverse Events	1
Cardiac failure acute 0/6 (0.00%)	Adverse Events	2
acute	HP:0011009,PATO:0000389	16-21
Cataract 0/6 (0.00%)	Adverse Events	3
cataract	HP:0000518,DOID:83	0-8
Cellulitis 1/6 (16.67%)	Adverse Events	4
cellulitis	HP:0100658,DOID:3488	0-10
Infection 0/6 (0.00%)	Adverse Events	5
Blood lactate dehydrogenase increased 0/6 (0.00%)	Adverse Events	6
blood	UBERON:0000178	0-5
lactate	CHEBI:24996	6-13
Anorexia 0/6 (0.00%)	Adverse Events	7
anorexia	HP:0002039	0-8
Femur fracture 0/6 (0.00%)	Adverse Events	8
femur fracture	HP:0031846	0-14
Brain oedema 0/6 (0.00%)	Adverse Events	9
brain	UBERON:0000955	0-5
Dyspnoea 1/6 (16.67%)	Adverse Events	10
Acute respiratory failure 0/6 (0.00%)	Adverse Events	11
acute	HP:0011009,PATO:0000389	0-5
respiratory failure	HP:0002878,DOID:11162	6-25
Catheterisation venous 0/6 (0.00%)	Adverse Events	12
Raynaud's phenomenon 0/6 (0.00%)	Adverse Events	13
Adverse Events 2:	Adverse Events	14
Total: 10	Adverse Events	15
Cardiac failure acute 1/62 (1.61%)	Adverse Events	16
acute	HP:0011009,PATO:0000389	16-21
Cataract 1/62 (1.61%)	Adverse Events	17
cataract	HP:0000518,DOID:83	0-8
Cellulitis 1/62 (1.61%)	Adverse Events	18
cellulitis	HP:0100658,DOID:3488	0-10
Infection 1/62 (1.61%)	Adverse Events	19
Blood lactate dehydrogenase increased 1/62 (1.61%)	Adverse Events	20
blood	UBERON:0000178	0-5
lactate	CHEBI:24996	6-13
Anorexia 1/62 (1.61%)	Adverse Events	21
anorexia	HP:0002039	0-8
Femur fracture 1/62 (1.61%)	Adverse Events	22
femur fracture	HP:0031846	0-14
Brain oedema 1/62 (1.61%)	Adverse Events	23
brain	UBERON:0000955	0-5
Dyspnoea 0/62 (0.00%)	Adverse Events	24
Acute respiratory failure 1/62 (1.61%)	Adverse Events	25
acute	HP:0011009,PATO:0000389	0-5
respiratory failure	HP:0002878,DOID:11162	6-25
Catheterisation venous 2/62 (3.23%)	Adverse Events	26
